Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
Leave a reply
Leave a Reply
You must be logged in to post a comment.
National Lymphedema Network
Empowering the Lymphology Community
